Safety and efficacy of eprosartan, a new angiotensin II receptor blocker

American Heart Journal

Volumn 138, Issue 3 II, 1999, Pages

  Shusterman, N H ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ENALAPRIL; EPROSARTAN; PLACEBO;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; COUGHING; ESSENTIAL HYPERTENSION; HEADACHE; HUMAN; MYALGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VERTIGO;

EID: 0032825062     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-8703(99)70316-9     Document Type: Review

References (28)

1. Hedner T, Samuelsson D, Lunde H, et al. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. Br Med J 1992;304:941-6.
2. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin converting enzyme inhibitor therapy. Ann Intern Med 1992;117:234-42.
3. Lunde H, Hedner T, Samuelsson D, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. Br Med J 1994;308:18-21.
4. Brooks DP, Ruffolo RR Jr. Functions mediated by peripheral angiotensin II receptors. In: Ruffolo RR Jr, editor. Angiotensin II receptors: molecular biology, biochemistry, pharmacology, and clinical perspectives. Boca Raton: CRC Press Inc; 1994. p. 71-102.
5. Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997;54:885-902.
6. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-311.
7. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998;55:713-8.
8. Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996;18:411-28.
9. Csajka C, Buclin T, Brunner HR, et al. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997;32:1-29.
10. Edwards RM, Aiyar N, Ohlstein EH, et al. Pharmacologic characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992;260:175-81.
11. Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997;62:417-25.
12. Brooks DP, Ruffolo RR Jr. Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Am Heart J 1999;138:S246-51.
13. Bottorff MB, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy 1999;19:73S-8S.
14. Gradman AH, Gray J, Maggiacomo F, et al. Evaluation of the angiotensin II receptor antagonist, eprosartan, administered once-daily in patients with essential hypertension [abstract]. Presented at the 2nd International Symposium on Angiotensin II Antagonism, London, February 1999.
15. Hedner T, Himmelmann A, Eprosartan Multi-National Study Group. The efficacy and tolerance of one- and two-daily doses of eprosartan in essential hypertension. J Hypertens. 1999;17:129-36.
16. Gavras H, Gavras I. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Curr Med Res Opin.1999;15:15-24.
17. Ponticelli C, Eprosartan Study Group. Comparison of the efficacy of eprosartan and enalapril in patients with severe hypertension [abstract]. Am J Hypertens 1997;10:128A.
18. Argenziano L, Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Curr Med Res Opin.1999;15:26-32.
19. Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Curr Med Res Opin. 1999;15:26-32.
20. Wilking SV, Belanger A, Kannel WB, et al. Determinants of isolated systolic hypertension. JAMA 1988;260:3451-5.
21. Krug-Gourley S, Harland D, Duff D, et al. Safety of eprosartan in elderly patients with hypertension [abstract]. Am J Hypertens 1998;11:78A.
22. Elliot W. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. J Hum Hypertens. In press.
23. Oparil S. Comparison of eprosartan and enalapril on incidence of cough in hypertensive patients with a history of ACE inhibitor-induced cough. Curr Ther Res. In press.
24. Rutan GH, McDonald RH, Kuller LH. A historical perspective of elevated systolic vs diastolic blood pressure from an epidemiological and clinical trial viewpoint. J Clin Epidemiol 1989;42:663-73.
25. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989;13:2-12.
26. Hall WD. Risk reduction associated with lowering systolic blood pressure: review of clinical trial data. Am Heart J 1999;138:S225-30.
27. McInnes GT. Integrated approaches to management of hypertension: promoting treatment acceptance. Am Heart J 1999;138:S252-5.
28. National High Blood Pressure Education Program. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). NIH publication No. 98-4080, 1997.